Who Is Allowed to Prescribe a Toxin — and Why the Remote-Prescribing Crackdown Matters

There is a step in cosmetic botulinum toxin treatment that most people never see and many do not know exists. Before anyone injects, the product has to be prescribed, because botulinum toxin is a prescription-only medicine. That single fact carries more safety weight than almost anything else in the process — and for years, the way it was handled in parts of the aesthetics industry quietly hollowed it out. Understanding the prescribing step, and why its tightening matters, explains a surprising amount about how the sector's harms happened and how they are meant to be prevented.

This is, at heart, a piece about accountability: who takes responsibility for the decision to put a potent neurotoxin into a particular person, and what it means when that responsibility is exercised by someone who never properly met them.

What "prescription-only" is supposed to mean

A prescription-only medicine is one judged to require the involvement of a qualified prescriber — a doctor, dentist, or appropriately qualified nurse or pharmacist prescriber — because using it safely needs clinical judgement. The prescriber is meant to assess the individual, decide whether the medicine is appropriate for them, consider their history and any contraindications, authorise a specific product and dose, and carry clinical responsibility for that decision.

For botulinum toxin, this matters because it is a potent substance whose safe use depends on the right product, the right dose, and the right candidate. The prescriber is the safeguard standing between the medicine and the patient — the person whose job is to say "yes, this, for you" or "no". The whole logic of prescription-only status assumes that judgement is exercised meaningfully.

How remote prescribing hollowed it out

In practice, a model grew up that preserved the form of prescribing while gutting its substance. A non-prescribing injector would carry out the treatment, and a remote prescriber — often someone the patient never met, sometimes contacted only briefly — would authorise the product. The assessment that prescribing is supposed to involve was, in many cases, reduced to a paperwork exercise: a form, a photo, a phone call, sometimes less. The prescriber signed off on people they had not genuinely evaluated, for treatments they would not perform, in settings they had not seen.

This is "remote prescribing", and the problem with it is not the use of distance per se but the evisceration of the clinical judgement that prescribing exists to provide. A prescriber who has not properly assessed the patient cannot meaningfully weigh contraindications or suitability. A prescriber who is not present cannot vouch for the product actually used, or ensure the dose authorised is the dose given. And a prescriber whose involvement is a formality is poorly placed to take real responsibility when something goes wrong — which means, in effect, that nobody clinically accountable was ever truly in the room.

That accountability vacuum is not incidental to the sector's harms; it is structurally connected to them. The same arrangements that treat prescribing as a formality are the arrangements most likely to tolerate unlicensed product, inappropriate candidates, and operators unequipped to manage complications.

Why the crackdown

This loophole is no longer merely frowned upon — it has been closed in guidance. The General Medical Council's position is that doctors must not prescribe injectable cosmetic medicines such as botulinum toxin remotely; a physical, face-to-face assessment of the patient is required before prescribing, and prescribing by telephone, video-link or online is not acceptable. Crucially, this is not a doctors-only rule: the other prescribing regulators — the General Dental Council, the General Pharmaceutical Council, and the Nursing and Midwifery Council — hold the same line, so the prohibition applies across all prescribing professions in aesthetics. A prescriber who continues to authorise toxin remotely is putting their registration at risk. What remains "in progress" is the broader licensing scheme around premises and practitioners; the remote-prescribing prohibition itself is already the expected standard.

This sits alongside two other strands covered elsewhere in this section: criminal enforcement against the supply of unlicensed and counterfeit toxin, and the broader licensing scheme for premises and practitioners. Together they form a logic. Licensing addresses who can perform procedures and where; enforcement addresses the product; and the prescribing crackdown addresses the clinical decision and the accountability behind it. Remove any one and the other two are weaker — which is why the prescribing step, invisible to most patients, is being treated as central rather than peripheral.

What it means in practice

For anyone thinking about treatment, the prescribing question is one of the most revealing things to understand, precisely because it is usually hidden. A model where a genuine prescriber properly assesses you in person, decides the toxin is appropriate, and authorises a specific licensed product is what the rules now require and the one that carries real clinical accountability. A model where the "prescription" is a remote formality attached to a treatment performed by someone else is precisely what the regulators have prohibited — and the one historically associated with the worst outcomes.

The deeper point is about responsibility. Aesthetic treatment with a prescription-only medicine is a clinical act, however much the surrounding setting resembles a salon. Someone qualified should be clinically responsible for the decision, and that responsibility cannot be discharged at a distance from a person they never meaningfully evaluated. The remote-prescribing crackdown is, in the end, an insistence that the accountability the law always implied is actually present.

Practical takeaways

• Botulinum toxin is a prescription-only medicine; a qualified prescriber is meant to assess the individual and take clinical responsibility for authorising it.
• "Remote prescribing" preserved the paperwork of prescribing while removing the judgement — prescribers authorising toxin for people they never properly assessed.
• That accountability vacuum is structurally linked to the sector's harms: unlicensed product, unsuitable candidates, and complications nobody was equipped to manage.
• Remote prescribing of cosmetic injectables is already prohibited in regulator guidance: a face-to-face assessment is required, and the rule applies across the GMC, GDC, GPhC and NMC.
• This works alongside enforcement against illegal product and the licensing of practitioners and premises — three strands of one safety logic.

What this doesn't mean

This is not a claim that all distance-based clinical care is unsafe, nor that every non-prescribing injector works unsafely. It is a specific point about a specific practice: reducing the prescribing of a potent neurotoxin to a remote formality removes the clinical judgement and accountability that prescription-only status exists to provide.

When to seek medical advice

This is an editorial explainer, not clinical guidance. If you are considering a treatment involving a prescription-only medicine, understanding who is taking clinical responsibility — and whether they have genuinely assessed you — is reasonable to ask about. Seek prompt medical attention for any complication after a procedure, and tell whoever assesses you exactly what was used.

A closing thought

The most important safeguard in cosmetic toxin treatment is one most patients never witness: a qualified person deciding, with real knowledge of you, that this medicine is appropriate, and standing behind that decision. Remote prescribing kept the signature and discarded the judgement. The crackdown is simply an effort to make the signature mean again what it was always supposed to mean — that someone qualified looked, thought, and took responsibility.

Further reading and sources

• General Medical Council — guidance for doctors offering cosmetic interventions and on prescribing
• Save Face — the ban on remote prescribing in aesthetics applies to all prescribing healthcare practitioners
• MHRA crackdown on illegal 'Botox' — GOV.UK
• House of Commons Library — the regulation of non-surgical cosmetic procedures in England

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.